摘要
目的 :探讨不同剂量阿托伐他汀联合阿司匹林治疗无症状性脑梗死的疗效及安全性。方法 :选取我院2013年7月至2014年7月收治的无症状性脑梗死患者128例,随机分为联合用药组(n=98)和对照组(n=30),对照组口服阿司匹林100 mg/d,联合用药组在对照组的基础上加用阿托伐他汀,按其阿托伐他汀剂量不同分为A组32例(10 mg/d)、B组34例(20 mg/d)和C组32例(30 mg/d)3个亚组。治疗14 d后检查患者的血脂情况、血小板凝集功能和不良反应,0.5年后超声检测患者的斑块数量及稳定性。结果 :用药前,组间血脂情况(CHOL、TG、LDL)、血小板凝集功能(CD62p、PAC-1、ET-1)、斑块数量和不稳定率比较差异无统计学意义;用药后,除HDL指标外,联合用药组患者上述指标均明显低于对照组(P<0.05),且随着阿托伐他汀剂量的增加,上述指标逐渐减少;联合用药组患者HDL指标均明显高于对照组(P<0.05),且随着阿托伐他汀剂量的增加,HDL逐渐增加(P<0.05);组间药物不良反应发生率比较差异无统计学意义。结论 :阿托伐他汀联合阿司匹林治疗无症状性脑梗死的疗效满意,安全性高,且随着阿托伐他汀剂量的增加,血脂情况、血小板凝集功能和斑块稳定性呈逐渐改善趋势。
Objective： To investigate the efficacy and safety of different doses of atorvastatin combined with aspirin in the treatment of asymptomatic cerebral infarction. Methods： One hundred and twenty-eight patients with asymptomatic cerebral infarction were selected in our hospital from July, 2013 to July, 2014, and randomly divided into a combined treatment group（n=98） and a control group（n=30）. Aspirin was orally administered at 100 mg/d in the control group, and in addition, atorvastatin was given to the combined treatment group. Subgroup A（10 mg/d, n=32）, B（20 mg/d, n=34） and C（30 mg/d, n=32） were further divided according to the different doses. Blood lipids, platelet aggregation function and adverse reactions were checked 14 days after treatment and the number and stability of plaques were detected by B ultrasound after 6 months. Results： Comparison of blood lipids（CHOL, TG, lipid profiles LDL and HDL）, platelet aggregation function（CD62p, PAC-1, ET-1）, the number of and unstable rate of plaques between two groups showed no significant difference before treatment while the above indexes except the HDL index were significantly lower in the combined treatment group than in the control group（P〈0.05） after treatment. The indexes decreased gradually with the increase of atorvastatin dose. HDL index was significantly higher in the combined treatment group than in the control group（P〈0.05）, and HDL increased gradually with the increase of atorvastatin dose（P〈0.05）. The differences of adverse drug reaction between two groups had no statistically significance. Conclusion： The curative effect of atorvastatin combined with aspirin is satisfactory for asymptomatic cerebral infarction with high safety, and blood lipid, platelet aggregation function and plaque stability are gradually improved with the increase of atorvastatin dose.
出处
《上海医药》
CAS
2015年第11期29-32,共4页
Shanghai Medical & Pharmaceutical Journal
基金
佛山市科技局立项(项目编号:200708068)
关键词
阿托伐他汀
阿司匹林
脑梗死
疗效
不良反应
atorvastatin aspirin cerebral infarction efficacy adverse reaction
